Dr. Wei Wei 韦玮
Chief Physician
Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of liver cancer, including standardized comprehensive therapy for intermediate and advanced stages, ctDNA methylation liquid biopsy for early diagnosis, and research on targeted immunotherapy resistance.
Dr. Wei holds a medical doctorate from Sun Yat-sen University. After working at the center since 2000, Dr. Wei was a visiting scholar at Austin Hospital, Australia (2009), and UC San Diego, USA (2015–2017). Currently a Chief Physician in Liver Surgery, Dr. Wei leads research on liver cancer combination therapies and ctDNA methylation biomarkers.
Name order: in Chinese the family name comes first (Wei Wei). Papers usually list the name as Wei Wei or Wei W.
Selected publications
133 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- JHEP Rep, 2026 (senior author): Systemic treatment patterns and clinical outcomes in hepatocellular carcinoma: A multicenter real-world study from China (STAR-HCC). PubMed 42595051
- BMC Med, 2026 (senior author): Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study. PubMed 42374487
- Signal Transduct Target Ther, 2026 (senior author): HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial. PubMed 42135293
- NPJ Precis Oncol, 2026 (senior author): HRD in endometrial cancer: LST loss drives distinct genomic profile and platinum response. PubMed 41772135
- Eur J Med Res, 2026 (senior author): DLGAP5 regulates malignancy and lenvatinib sensitivity of hepatocellular carcinoma through AKT/mTOR/NF-κB pathway. PubMed 41664119
- Int J Med Sci, 2025 (senior author): Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion. PubMed 40084258
- Int Immunopharmacol, 2024 (senior author): The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients. PubMed 38950459
- J Immunother Cancer, 2022 (first author): Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. PubMed 35623659
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion